^
No biomarker
Bladder Cancer
AU-011
Sensitive: B - Late Trials
Aura Biosciences Press Release - 4 days - (New B)
CREBBP mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Res - 2 weeks - (New C3)
No biomarker
Bladder Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Bladder Cancer
EP
Sensitive: A2 - Guideline
PD-L1 expression
Bladder Cancer
atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
carboplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
enfortumab vedotin
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
gemcitabine + ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
avelumab
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
sacituzumab govitecan-hziy
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
nivolumab
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
ddMVAC
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
inbakicept
Sensitive: B - Late Trials
PD-L1 expression
Bladder Cancer
nivolumab
Sensitive: B - Late Trials
HLA-A*03
Bladder Cancer
CTLA4 inhibitor
Resistant: B - Late Trials
HLA-A*03
Bladder Cancer
PD-L1 inhibitor
Resistant: B - Late Trials
HLA-A*03
Bladder Cancer
PD1 inhibitor
Resistant: B - Late Trials
PD-L1 expression
Bladder Cancer
durvalumab
Sensitive: C1 - Off-label
TMB-H
Bladder Cancer
pembrolizumab
Sensitive: C1 - Off-label
FGFR3 mutation
Bladder Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
FGFR1 amplification
Bladder Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
TET1 mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
BIRC5 expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
12-CK gene signature
Bladder Cancer
atezolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
RB1 mutation + PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
DDR + PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
RB1 mutation
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
PBRM1 mutation
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
SBS5 signature
Bladder Cancer
cisplatin
Sensitive: C3 – Early Trials
BRCA2 mutation
Bladder Cancer
cisplatin
Sensitive: C3 – Early Trials
PD-1 expression
Bladder Cancer
cisplatin
Sensitive: C3 – Early Trials
TMB-H
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 amplification
Bladder Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
PBRM1 mutation
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
NOTCH1 mutation + TMB-L + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
ELF3 mutation + TMB-L + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
ELF3 mutation + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
NOTCH1 mutation + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
PIK3CA mutation + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
PD-L1 overexpression
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
IFNG positive signature
Bladder Cancer
durvalumab
Sensitive: C3 – Early Trials
PTEN expression
Bladder Cancer
everolimus
Sensitive: C3 – Early Trials
HER-2 overexpression
Bladder Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
IFNA1 expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
IFNG expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
TSC1 mutation
Bladder Cancer
everolimus
Sensitive: C3 – Early Trials
PD-L1 expression
Bladder Cancer
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
HER-2 mutation + TMB-H
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
ERBB3 mutation + TMB-H
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
PCSK9 underexpression
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
LRP1B mutation + TMB-H
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
DDR
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
CXCL13 expression
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
RAD52 underexpression
Bladder Cancer
cisplatin
Resistant: C3 – Early Trials
RNF43 mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
KMT2C mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1-H
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
TDO2 overexpression
Bladder Cancer
cetuximab
Resistant: C3 – Early Trials
TLR4-L
Bladder Cancer
gemcitabine
Sensitive: C3 – Early Trials
ARID1A mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
KIFC1 expression
Bladder Cancer
atezolizumab
Sensitive: C3 – Early Trials
HLA-A*03
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
High MHC-II signature
Bladder Cancer
sunitinib
Sensitive: C3 – Early Trials
High MHC-II signature
Bladder Cancer
NU7441
Sensitive: C3 – Early Trials
High MHC-II signature
Bladder Cancer
docetaxel
Sensitive: C3 – Early Trials
High MHC-II signature
Bladder Cancer
cisplatin
Sensitive: C3 – Early Trials
BRCA1 underexpression
Bladder Cancer
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
ERCC1 underexpression
Bladder Cancer
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
CALCR overexpression
Bladder Cancer
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
GNG4 overexpression
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
CD8 overexpression
Bladder Cancer
atezolizumab
Sensitive: C3 – Early Trials
MAST4 mutation
Bladder Cancer
GC
Resistant: C3 – Early Trials
ITGAX underexpression
Bladder Cancer
anlotinib
Sensitive: C3 – Early Trials
PIK3CA M1043I
Bladder Cancer
everolimus
Sensitive: C4 – Case Studies
MSH4 L359I
Bladder Cancer
atezolizumab
Sensitive: C4 – Case Studies
TSC1 1907_1908del
Bladder Cancer
everolimus
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Bladder Cancer
erdafitinib
Sensitive: C4 – Case Studies
ERCC2 E606Q
Bladder Cancer
cisplatin + gemcitabine
Sensitive: C4 – Case Studies
ERCC2 E606Q
Bladder Cancer
carboplatin + gemcitabine
Sensitive: C4 – Case Studies